ImmunityBio, Inc.IBRXNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Year-over-year gross profit growth rate
Latest
6.25%
↓ 97% below average
Average (39q)
234.90%
Historical baseline
Range
High:7566.67%
Low:-1574.17%
CAGR
-4.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 6.25% |
| Q2 2025 | 59.72% |
| Q1 2025 | 117.94% |
| Q4 2024 | 23.68% |
| Q3 2024 | 483.19% |
| Q2 2024 | 2517.50% |
| Q1 2024 | -71.22% |
| Q4 2023 | 69.51% |
| Q3 2023 | 100.00% |
| Q2 2023 | 100.69% |
| Q1 2023 | 13.03% |
| Q4 2022 | -16.19% |
| Q3 2022 | 0.66% |
| Q2 2022 | -9.31% |
| Q1 2022 | -1483.08% |
| Q4 2021 | 490.91% |
| Q3 2021 | -80.53% |
| Q2 2021 | 143.88% |
| Q1 2021 | 106.24% |
| Q4 2020 | -1574.17% |
| Q3 2020 | -65.37% |
| Q2 2020 | 164.24% |
| Q1 2020 | -82.07% |
| Q4 2019 | 7566.67% |
| Q3 2019 | -29.41% |
| Q2 2019 | 240.00% |
| Q1 2019 | -28.57% |
| Q4 2018 | -77.42% |
| Q3 2018 | 675.00% |
| Q2 2018 | -20.00% |
| Q1 2018 | -58.33% |
| Q4 2017 | 50.00% |
| Q3 2017 | -42.86% |
| Q2 2017 | 27.27% |
| Q1 2017 | -21.43% |
| Q4 2016 | 16.67% |
| Q3 2016 | 0.00% |
| Q2 2016 | 100.00% |
| Q1 2016 | -57.14% |
| Q4 2015 | 40.00% |